These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 37426619)

  • 21. Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.
    Islam MA; Kibria MK; Hossen MB; Reza MS; Tasmia SA; Tuly KF; Mosharof MP; Kabir SR; Kabir MH; Mollah MNH
    Sci Rep; 2023 Mar; 13(1):4685. PubMed ID: 36949176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in the Total Synthesis of Antitumor Tetrahydroisoquinoline Alkaloids.
    Gao Y; Tu N; Liu X; Lu K; Chen S; Guo J
    Chem Biodivers; 2023 May; 20(5):e202300172. PubMed ID: 36939065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches.
    Qi JH; Chen PY; Cai DY; Wang Y; Wei YL; He SP; Zhou W
    Front Endocrinol (Lausanne); 2022; 13():1096655. PubMed ID: 36699034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
    Hill DD; Kramer JR; Chaffin KR; Mast TC; Robertson MN; Kanwal F; Haber BA
    Ann Hepatol; 2023; 28(2):100899. PubMed ID: 36632975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19.
    Al-Kuraishy HM; Al-Gareeb AI; Albogami SM; Jean-Marc S; Nadwa EH; Hafiz AA; A Negm W; Kamal M; Al-Jouboury M; Elekhnawy E; Batiha GE; Waard M
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36355535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saquinavir: From HIV to COVID-19 and Cancer Treatment.
    Pereira M; Vale N
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.
    Tortorici MA; Walls AC; Joshi A; Park YJ; Eguia RT; Miranda MC; Kepl E; Dosey A; Stevens-Ayers T; Boeckh MJ; Telenti A; Lanzavecchia A; King NP; Corti D; Bloom JD; Veesler D
    Cell; 2022 Jun; 185(13):2279-2291.e17. PubMed ID: 35700730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir.
    Jain P; Thota A; Saini PK; Raghuvanshi RS
    Crit Rev Anal Chem; 2024; 54(2):401-415. PubMed ID: 35617468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron.
    Su J; Zheng J; Huang W; Zhang Y; Lv C; Zhang B; Jiang L; Cheng T; Yuan Q; Xia N; Zhang J; Li L; Li L; Deng X
    Signal Transduct Target Ther; 2022 May; 7(1):167. PubMed ID: 35610213
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?
    Barnieh FM; Loadman PM; Falconer RA
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188641. PubMed ID: 34695533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of SARS-CoV-2 entry into cells.
    Jackson CB; Farzan M; Chen B; Choe H
    Nat Rev Mol Cell Biol; 2022 Jan; 23(1):3-20. PubMed ID: 34611326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins.
    Halder UC
    J Biol Res (Thessalon); 2021 Aug; 28(1):18. PubMed ID: 34344455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.
    Lo HS; Hui KPY; Lai HM; He X; Khan KS; Kaur S; Huang J; Li Z; Chan AKN; Cheung HH; Ng KC; Ho JCW; Chen YW; Ma B; Cheung PM; Shin D; Wang K; Lee MH; Selisko B; Eydoux C; Guillemot JC; Canard B; Wu KP; Liang PH; Dikic I; Zuo Z; Chan FKL; Hui DSC; Mok VCT; Wong KB; Mok CKP; Ko H; Aik WS; Chan MCW; Ng WL
    ACS Cent Sci; 2021 May; 7(5):792-802. PubMed ID: 34075346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets.
    Romeo I; Mesiti F; Lupia A; Alcaro S
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33530467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
    Wang R; Simoneau CR; Kulsuptrakul J; Bouhaddou M; Travisano KA; Hayashi JM; Carlson-Stevermer J; Zengel JR; Richards CM; Fozouni P; Oki J; Rodriguez L; Joehnk B; Walcott K; Holden K; Sil A; Carette JE; Krogan NJ; Ott M; Puschnik AS
    Cell; 2021 Jan; 184(1):106-119.e14. PubMed ID: 33333024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
    Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
    Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.